Finance
Novo Nordisk shares rise 5% on upbeat reaction to diabetes conference
Published by Global Banking & Finance Review®
Posted on September 18, 2025
1 min readLast updated: January 21, 2026
Global Banking & Finance Review®
Company
Published by Global Banking & Finance Review®
Posted on September 18, 2025
1 min readLast updated: January 21, 2026
Novo Nordisk shares rose 5.4% after a positive reaction at a diabetes conference, with strategic shifts under new CEO Maziar Mike Doustdar.
COPENHAGEN (Reuters) - Novo Nordisk's shares rose by 5.4% on Thursday as investors turned more positive about the Danish drugmaker's prospects following a key diabetes conference held in Vienna this week.
Novo's shares plunged in July when the company issued a profit warning and announced that a veteran company insider, Maziar Mike Doustdar, would become its new CEO on August 7.
He has since announced large staff cuts to reduce costs, helping the stock regain some of the recent losses.
Novo Nordisk did not unveil groundbreaking data at the European Association for the Study of Diabetes conference, but the company was "changing commercial focus" under Doustdar, analysts at Barclays said in a research note.
"Collectively, these moves suggest Novo is positioning itself to sharpen execution and more effectively compete with Eli Lilly," Barclays wrote.
German brokers Baader said Novo Nordisk was a "a compelling opportunity" to invest in after the stock's fall of roughly 60% over the past 15 months.
(Reporting by Maggie Fick and Stine Jacobsen, editing by Terje Solsvik)
Novo Nordisk's shares rose by 5.4% as investors reacted positively to the company's prospects following a key diabetes conference in Vienna.
Novo Nordisk appointed Maziar Mike Doustdar as its new CEO and announced large staff cuts to reduce costs, which helped the stock recover some losses.
No, Novo Nordisk did not unveil groundbreaking data at the European Association for the Study of Diabetes conference, but it is changing its commercial focus under the new CEO.
Analysts from Baader described Novo Nordisk as a 'compelling opportunity' for investment after the stock fell approximately 60% over the past 15 months.
Analysts noted that Novo Nordisk is positioning itself to more effectively compete with Eli Lilly in the diabetes market.
Explore more articles in the Finance category
